Kriya Medical Technologies bags DCGI license for RT-PCR kit KRIVIDA Novus

Published On 2022-02-15 07:12 GMT | Update On 2022-02-15 07:16 GMT

New Delhi: Medical devices firm Kriya Medical Technologies has recently received manufacturing licence from the DCGI (Drugs Controller General of India) for its product KRIVIDA Novus, an RT-PCR kit that can detect the Omicron variant and its sub-lineages in 45 minutes. The product has been developed in collaboration with ImmuGenix Bioscience. Priced at Rs 150 plus taxes, the test is...

New Delhi: Medical devices firm Kriya Medical Technologies has recently received manufacturing licence from the DCGI (Drugs Controller General of India) for its product KRIVIDA Novus, an RT-PCR kit that can detect the Omicron variant and its sub-lineages in 45 minutes. The product has been developed in collaboration with ImmuGenix Bioscience.

Priced at Rs 150 plus taxes, the test is affordable and most suitable for entry point screening at airports, the company said in a statement.

The SARS-CoV-2 Test Kit (Real-time PCR) is an in vitro diagnostic real-time reverse transcription-PCR assay intended for the qualitative detection of nucleic acid from SARS-CoV-2 in nasopharyngeal/oropharyngeal swabs, anterior/mid-turbinate nasal swabs, nasopharyngeal washes/aspirates or nasal aspirates, and bronchoalveolar lavage (BAL) specimens from individuals suspected of COVID-19 by their healthcare provider.

The company said it will roll out the kit from its Chennai-based manufacturing facility. The company currently has a production capacity of 5 million tests per month and plans to increase it to 10 million tests per month within the next two weeks.

Read also: Roche Diagnostics launches Covid-19 at-home test kit

''Our focus is to make testing for Covid-19 variants faster, affordable and accessible to everyone, thereby enabling swift prevention and timely treatment. Since KRIVIDA Novus can detect the Omicron variant (B.1.1.529) and all its sub-lineages, such as BA.1, BA.2 and BA.3 in 45 minutes, it is most ideal and beneficial for entry point screening at airports and remobilisation of normal conditions in workplace and institutions," Kriya Medical Technologies CEO and Founder Anu Moturi noted.

"Kriya's KRIVIDA NOVUS SARS-COV-2 REAL-TIME PCR KIT leverages cutting edge gene sequencing technology to not only detect positive COVID cases, but, in a single test, differentiate which strain has been contracted," the company said in a statement.

Read also: ICMR approves Odisha made COVID rapid antigen test kit

Article Source : with inputs

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Ruchika Sharma

Ruchika Sharma joined Medical Dialogue as an Desk Editor for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Kriya Medical Technologies bags DCGI license for RT-PCR kit KRIVIDA Novus

Similar News